DelveInsight’s Triple Negative Breast Cancer Market Insights Report offers a detailed analysis of Disease, its causes, symptoms, diagnostics modalities and treatment options.
The report also offers comprehensive insights into Triple Negative Breast Cancer market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing Triple Negative Breast Cancer clinical trials, collaboration in the space, and key pharmaceutical companies actively pushing the growth of Triple-Negative Breast Cancer market size forward.
Some of the key highlights from the Triple Negative Breast Cancer Market Insights:
- TNBC Market Size in the 7MM was found to be USD 438 Million in 2017.
- The US accounted for the largest market size of TNBC, in comparison to the other 7MM countries
- Total Diagnosed Incident cases of TNBC in the 7MM countries was 99,380 in 2017
- Amongst all the 7MM countries, the EU-5 countries (combined) accounted for the highest number of incident cases, followed by the US in the year 2017
- Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC and accounted for 12,516 cases, followed by France and Italy in the year 2017.
- Upcoming therapies such as Ipatasertib (Hoffmann-La Roche), Pembrolizumab (Imprime PGG; HiberCell), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn) and CFI-400945 (Treadwell Therapeutics) have the potential to create a significant positive shift in the TNBC market size during the study period.
Request for free Sample Report: https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market
Triple-Negative Breast Cancer Overview:
Triple-Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.
Through various secondary domains, it can be concluded that TNBC affects females.
Triple-Negative Breast Cancer Symptoms:
Symptoms include Breast pain or redness, A lump or mass in the breast and a nipple that turns inward or has a discharge.
For more insights into Disease, causes and treatment, reach out to Triple-Negative Breast Cancer Treatment Landscape.
Triple-Negative Breast Cancer Epidemiology Segmentation
The Triple Negative Breast Cancer Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:
- Triple-Negative Breast Cancer Prevalence
- Severity Specific Triple Negative Breast Cancer Prevalence
- Diagnosed and Treatable Cases of Triple-Negative Breast Cancer
Triple-Negative Breast Cancer Pipeline Therapies and Key Companies
- Lynparza: AstraZeneca
- Tercentriq (Atezolizumab): Hoffmann-La Roche
- Sacituzumab Govitecan-hziy: Immunomedics
- Keytruda: Merck
- Imprime PGG : HiberCell
- Ipatasertib: Hoffmann-La Roche
- IPI-549: Infinity Pharmaceuticals
- Leronlimab (PRO 140): CytoDyn
- And Many Others
Request for free Sample Report: https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-market
Scope of the Report
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Triple-Negative Breast Cancer, covering causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight into Triple Negative Breast Cancer epidemiology and treatment in the 7MM
- Current and emerging therapies for Triple-Negative Breast Cancer
- Triple-Negative Breast Cancer market drivers and barriers
Table of Contents
|3||Competitive Intelligence Analysis for Triple Negative Breast Cancer|
|4||Triple Negative Breast Cancer Market Overview at a Glance|
|5||Executive Summary of Triple Negative Breast Cancer|
|6||Triple Negative Breast Cancer Epidemiology and Market Methodology|
|7||Triple Negative Breast Cancer Epidemiology and Patient Population|
|8||Triple Negative Breast Cancer Patient Journey|
|9||Treatment Algorithm, Current Treatment, and Medical Practices|
|10||Key Endpoints in Triple Negative Breast Cancer Clinical Trials|
|11||Triple Negative Breast Cancer Marketed Therapies|
|12||Triple Negative Breast Cancer Emerging Therapies|
|13||Triple Negative Breast Cancer: 7 Major Market Analysis|
|15||Access and Reimbursement Overview of Triple Negative Breast Cancer|
|18||Triple Negative Breast Cancer Market Drivers|
|19||Triple Negative Breast Cancer Market Barriers|
DelveInsight is a leading Market Research, and Business Consultant focused purely on life sciences. It assists pharma companies by providing them with end-to-end solutions to boost their performance.
Get access to all the Pharma and healthcare market research reports through our market research subscription-based platform PharmDelve.
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States